$PSTV - Why I’m holding through 2026. This isn't your typical "hope and pray" biotech

Listen, we all know the drill with micro-cap biotechs: they burn cash, have zero revenue, and pray for an FDA miracle. I’ve been digging into Plus Therapeutics ($PSTV), and the setup here is actually legit. It’s not just a "maybe" company; they have a "now" product. *The "Floor": CNSide is already making money* Most biotechs have $0 revenue. PSTV has CNSide. It’s a diagnostic test for brain/spine cancer that is miles ahead of the old-school methods. - The Flex: It’s 92% accurate. In 90% of cases, doctors actually changed their treatment plan after seeing the results. - The Money: This isn't a lab dream; it’s being used in 120+ cancer centers. They just signed national deals with Humana and UnitedHealthcare (67M+ people covered). Even a small bump in test volume makes the current $76M market cap look stupidly low. *The "Ceiling": REYOBIQ (The Big Catalyst)* This is their "liquid" radiation therapy. Instead of blasting the whole brain, they inject it right where it's needed. - Data: They’re seeing a 75% clinical benefit rate in trials. - Timing: They just had a "constructive" meeting with the FDA. Expect the roadmap for the final (pivotal) trial any day now. *The "Smart Money" is buying (Hard)* This is what caught my eye. - BlackRock increased their position by 6,000% recently. Vanguard is in. - The CEO (Marc Hedrick) just got a boatload of shares and instead of selling some to pay the taxes (like every other CEO), he paid the IRS out of his own pocket to keep every single share. - The CFO bought 20k shares at $0.51 with his own cash on the open market. They know something is coming. *​The Boring (but important) Stuff* - Cash: ~$16.6M + grants. They’re good until late 2026. - Compliance: They have until May to hit $1.00 for Nasdaq. Looking at the chart, they’re trying to do it organically, not with a crappy reverse split. - Debt: Low. They’re lean. *Bottom Line* You’ve got a $0.55 stock with a $7.25 analyst target. You’ve got insiders buying and big institutions loading up. It’s a diagnostic play (revenue) + a pharma play (moonshot) in one. ​I’m in. Are you?